Rucaparib (AG-014699,PF-01367338) phosphate

Catalog No.S1098

Rucaparib (AG-014699,PF-01367338) phosphate Chemical Structure

Molecular Weight(MW): 421.36

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 55 Publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.
Features The first PARP inhibitor used in clinical trials combined with temozolomide.
Targets
PARP [1]
(Cell-free assay)
1.4 nM(Ki)
In vitro

Rucaparib is a potent inhibitor of purified full-length human PARP-1 and shows higher inhibition of cellular PARP in LoVo and SW620 cells. Besides, Rucaparib binds detectably to eight other PARP domains, including PARP2, 3, 4, 10, 15, 16, TNKS1 and TNKS2. [1] [2] The radio-sensitization by Rucaparib is due to downstream inhibition of activation of NF-κB, and is independent of SSB repair inhibition. Rucaparib could target NF-κB activated by DNA damage and overcome toxicity observed with classical NF-κB inhibitors without compromising other vital inflammatory functions. [3] Rucaparib inhibits PARP-1 activity by 97.1% at a concentration of 1 μM in permeabilised D283Med cells. [4]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BT-474 M4XY[GZ2dmO2aX;uJGF{e2G7 NHPyPIYxNjFxMT:1NFAwOTByMDDuUS=> MXfpcohq[mm2czDQRXJRKGGldHn2bZR6KGG2IIP0ZZJ1cW6pIHPvcoNmem62cnH0bY9vKG:oIEWwNEBvVQ>? NHzjN4QzPTF{OES1OS=>
BT474 MmL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjGOVAxKG6P M1LVR|Ex6oDVMUZCpIQ> NFizSJlz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIITo[UBnd3W{IHzpcoV{KGGwZDDzbYdvcW[rY3HueIx6 M3;mSlI2OTJ6NEW1
SKBR3 NUn6UVE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\UbIZtPTByIH7N M13FeVEx6oDVMUZCpIQ> NEnTeIdz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIITo[UBnd3W{IHzpcoV{KGGwZDDzbYdvcW[rY3HueIx6 MWGyOVEzQDR3NR?=
AU565 MmjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:0N|UxOCCwTR?= M2TP[lEx6oDVMUZCpIQ> NU\BO4M6emWmdXPld{Bk\WyuIHfyc5d1cCCrbjD0bIUh\m:3cjDsbY5meyCjbnSgd4lodmmoaXPhcpRtgQ>? Mm\VNlUyOjh2NUW=
EFM192A NWO2PYRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPLbHI2ODBibl2= NHjaPHoyOOLCk{G1xsBl MXHy[YR2[2W|IHPlcIwh\3Kxd4ToJIlvKHSqZTDmc5VzKGyrbnXzJIFv\CC|aXfubYZq[2GwdHz5 M17WXFI2OTJ6NEW1
MDA-MB-231 MUfGeY5kfGmxbjDBd5NigQ>? MYCxNE8zOC92MDFOwG0> NEnENlAzPCCq NHX0NplqdmO{ZXHz[ZMheC2DS2SgcIV3\Wy|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NX7PVXhsOjR2MkCxOVI>
MDA-MB-231 MYrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3XVXlAvOS12MDFOwG0> NUL6dYhZOjRiaB?= NITCSIJKSzVy4pEJQgKBkTF5Lke3xsDPxE1? MlK3NlQ1OjBzNUK=
MDA-MB-231 MkjDRZBweHSxc3nzJGF{e2G7 Mmi3NVAwOjBxNECg{txO MYmyOEBp NX\XfWRGcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> NVf6eotLOjR2MkCxOVI>
MDA-MB-231 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[xNE8zOC92MDFOwG0> NWO5OVJ7OjRiaB?= MX7icI9kc3NiY3XscEBkgWOuZTDwdo9oemW|c3nvckBqdiCJMj;NJJBp[XOn MY[yOFQzODF3Mh?=
H460 NXXxVHFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrGTJg1ODBibl2= MoTqNlTDqGh? M{XmeYlv[3KnYYPld{Bk\WyudXzhdkBz[WSrb4PlcpNqfGm4aYT5 MkS0NlQ1OTF4MUG=
A549  NIDQV3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP1OFAxKG6P MXGyOOKhcA>? NV[zb3BjcW6lcnXhd4V{KGOnbHz1cIFzKHKjZHnvd4Vve2m2aY\peJk> NY\rR5poOjR2MUG2NVE>
DT40 M1P5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlv5TWM2OD1{MTDuUS=> NVXpfZBYOjR|NU[4NVM>
DU145 MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3kd3VkUUN3ME2xPEBvVQ>? MUSyOFM2PjhzMx?=
COLO704 M4q1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHPWmNKSzVyPUKuOVIhyrFiMD62O{DPxE1? Mn7TNlM4Ojl2MEK=
OVMANAb M3Puc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmD3TWM2OD1{LkW4JOKyKDBwM{ig{txO M1T2PVI{PzJ7NECy
OV177 NXHrXYdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnBTWM2OD1{Lke4JOKyKDBwN{Gg{txO M2XxdFI{PzJ7NECy
OAW28 M13nXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPVZpNKSzVyPUOuOlEhyrFiMD6yPEDPxE1? M1vzS|I{PzJ7NECy
OVSAHO MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILNO3FKSzVyPUOuOlQhyrFiMD6zN{DPxE1? MVyyN|czQTRyMh?=
OVKATE M1S4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoOwTWM2OD1|Lk[0JOKyKDFwN{mg{txO M1:0S|I{PzJ7NECy
OVCAR3 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\ORnpHUUN3ME2zMlc1KMLzIECuOFAh|ryP NID1[ZAzOzd{OUSwNi=>
PEO14 M4G0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3R[olFUUN3ME2zMlg1KMLzIECuO|Yh|ryP NF7SVmEzOzd{OUSwNi=>
A2780 M2PXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHQcWs2UUN3ME2zMlk1KMLzIECuNlUh|ryP MX6yN|czQTRyMh?=
OVTOKO NV\UWVJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYH3TnJOUUN3ME20MlE1KMLzIEGuOVMh|ryP MUGyN|czQTRyMh?=
KURAMOCHIb MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LrSGlEPTB;ND6zOEDDuSByLkK5JO69VQ>? NF7iS|MzOzd{OUSwNi=>
TOV21G Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkP2TWM2OD13LkC3JOKyKDFwM{Cg{txO NYLiTnJrOjN5Mkm0NFI>
OVISE MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrVRWZKSzVyPUWuOlghyrFiMD6yN{DPxE1? MXuyN|czQTRyMh?=
KK MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnIVmt3UUN3ME22MlE2KMLzIEGuOFIh|ryP NHXW[mEzOzd{OUSwNi=>
RMUGS NVrpOXhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTdwMEOgxtEhOS56MzFOwG0> MX2yN|czQTRyMh?=
PEO6 NELYZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3z2d2lEPTB;Nz6wOkDDuSByLke0JO69VQ>? M3TodVI{PzJ7NECy
OVCA429 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnLTlJ6UUN3ME24MlI6KMLzIEGuOlQh|ryP MW[yN|czQTRyMh?=
OV167 MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTUNXBtUUN3ME24MlM{KMLzIEGuNVgh|ryP NWXvbmNvOjN5Mkm0NFI>
RMG1 MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XlVGlEPTB;OT6zNkDDuSB{LkO2JO69VQ>? MnrRNlM4Ojl2MEK=
OVCAR5 M1voOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUK1XIpXUUN3ME25MlUxKMLzIEKuOVkh|ryP MYSyN|czQTRyMh?=
EFO21 MoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1uwcWlEPTB;OT65NkDDuSBzLki3JO69VQ>? NEf3S2YzOzd{OUSwNi=>
ES2 MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzNTWM2OD1zMD6xNkDDuSBzLkKzJO69VQ>? MnHnNlM4Ojl2MEK=
Tyk-nu NVS2RVgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M36zcGlEPTB;MUCuNlAhyrFiMT6xNkDPxE1? M4LNfFI{PzJ7NECy
CAOV3 NUjVbpJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnk[XRKSzVyPUGwMlM4KMLzIECuPFch|ryP NHfYR3AzOzd{OUSwNi=>
OV207 MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGW5[mtKSzVyPUGyMlI4KMLzIECuN|Ih|ryP NXLpVJlGOjN5Mkm0NFI>
HEY NXj5dIZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTF|LkCxJOKyKDBwN{Wg{txO MWKyN|czQTRyMh?=
DOV13 Mk[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPQW21KSzVyPkG1JO69VQ>? NXzwbXFIOjN5Mkm0NFI>
EFO27 M3nncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRjF3IN88US=> NFy4ZWozOzd{OUSwNi=>
HEY C2 NGD0UIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLlcoxkUUN3ME6xOUDPxE1? MorYNlM4Ojl2MEK=
KOC-7cc NYfXd|l5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{L2bWlEPTB-MUWg{txO M4nwUlI{PzJ7NECy
MCASb MoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rvTWlEPTB-MUWg{txO NYnte5pbOjN5Mkm0NFI>
OAW42 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXEN|hKSzVyPkG1JO69VQ>? NFLXVWgzOzd{OUSwNi=>
OV2008 NH3id4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXGxWIRCUUN3ME6xOUDPxE1? NEGzbJUzOzd{OUSwNi=>
OV90 NXXRN|A4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmS3TWM2OD5zNTFOwG0> MkHoNlM4Ojl2MEK=
OVCA420b NVrjWnRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETScotKSzVyPkG1JO69VQ>? MlfUNlM4Ojl2MEK=
OVCA432 NFmzUWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DMfmlEPTB-MUWg{txO M2PBOlI{PzJ7NECy
PEA2 MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4q0SWlEPTB-MUWg{txO NGTFbmUzOzd{OUSwNi=>
SKOV3 NF7WfHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XMdGlEPTB-MUWg{txO MlLXNlM4Ojl2MEK=
TOV112D NXP5Z3pVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmH2NE0{KM7:TR?= M3O2bmlEPTB-MUWg{txO MoH5NlM4Ojl2MEK=
C4-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV[wMVMh|ryP MXSxOEBl M2LvbGROW09? Mnnw[IVkemWjc3XzJINwdG:weTDueY1j\XJiZH;z[UBl\XCnbnTlcpRtgQ>? NE\vWHYzOzV4NUK0OC=>
PC3 MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33INFAuOyEQvF2= NEW2[mUyPCCm MVnEUXNQ MVzk[YNz\WG|ZYOgZ49td267IH71cYJmeiCmb4PlJIRmeGWwZHXueIx6 MV2yN|U3PTJ2NB?=
DU145 M4T0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXqVoc2OC1|IN88US=> M{jY[FE1KGR? NF\5b4lFVVOR M1vPN4Rm[3KnYYPld{Bkd2yxbomgcpVu[mW{IHTvd4Uh\GWyZX7k[Y51dHl? NI\HW4kzOzV4NUK0OC=>
VCaP  Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTa[FkxNTNizszN NWLDOWJOOTRiZB?= MlT4SG1UVw>? MoO3[IVkemWjc3XzJINwdG:weTDueY1j\XJiZH;z[UBl\XCnbnTlcpRtgQ>? MmnRNlM2PjV{NES=
LNCaP  MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3ENE0{KM7:TR?= M{TYUFE1KGR? NVTReoFFTE2VTx?= MXPk[YNz\WG|ZYOgZ49td267IH71cYJmeiCmb4PlJIRmeGWwZHXueIx6 NHy5WHczOzV4NUK0OC=>
MDA-MB-468 NULnfm1xS2WubDDWbYFjcWyrdImgRZN{[Xl? MXrJR|UxRTlwNzFOwG0> NH\1XlQzOjZ5OEG2NS=>
MDA-MB-231 MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NULiboY{UUN3ME2xN{DPxE1? NWLkS|VrOjJ4N{ixOlE>
Cal-51 NHPtVmRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGXmTZFKSzVyPUiuOkDPxE1? M{HJbFIzPjd6MU[x

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
PAR; 

PubMed: 27960087     


MCF-7 cells were pretreated ± Rucaparib (15 µM, 2 hr), then ± Rucaparib (15 µM) or two different doses of β-lap (2.0 or 5.0 µM) for 2 hr. Levels of PAR (PARP hyperactivation) formation were assessed with α-tubulin as loading controls.

BRCA1; 

PubMed: 24085845     


MCF7 cells, MDA-MB-436 parental cells and resistant clones RR-1, RR-5, and RR-6 were treated with DMSO (−) or 1 µM rucaparib (+) for 24 h, and BRCA1 protein levels were assessed by using BRCA1 N- or C-terminal-specific antibodies by Western blot. 

27960087 24085845
Growth inhibition assay
Cell viability; 

PubMed: 31119062     


The effect of rucaparib on proliferation of keloid fibroblasts. (A) Keloid cell growth following treatment with rucaparib at various concentration (0, 2, 10, 20 μM) was evaluated by MTT assays. Data are expression as mean standard deviation of percent changes of triplicate optical densities. (B) Rucaparib (20 μM) significantly decreased proliferation of keloid fibroblasts. The combination of rucaparib (20 μM) and triamcinolone (50 μM) showed additive suppressive effect on keloid fibroblasts as compared with rucaparib single therapy. Data are expression as mean standard deviation of percent changes of triplicate optical densities. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.

31119062
Immunofluorescence
α-tubulin; 

PubMed: 30589644     


Representative immunofluorescence images of DMSO-, rucaparib- (Ruca-), and Ola-exposed A549-ERCC1(WT/WT) and A549-ERCC1(–/–) cells. Cells were exposed to 15 μM Ruca or 40 μM Ola during 72 hours. White arrows, CCFs; yellow arrows, micronuclei. Scale bar: 20 μm. 

PAR; 

PubMed: 27515310     


Cells were treated with 20 mM hydrogen peroxide (H2O2) in order to stimulate PARP-1 activity in the presence or absence of the PARP-1 inhibitors rucaparib and olaparib. Poly(ADP-ribose) (PAR) chain synthesis was detected using an anti-PAR monoclonal Alexa Fluor 488-conjugated antibody (green). The nucleus was visualised using the nuclear counterstain DAPI (blue). Representative images obtained from the analysis of anti-PAR staining of SK-N-BE(2c) cells are shown.

γH2AX; 

PubMed: 23565244     


γH2AX foci was determined by immunofluoresecence microscopy at 24 h following combined treatment with radiation and rucaparib in PC3 and LNCaP cells. 

53BP1; 

PubMed: 23565244     


53BP1 foci was determined by immunofluoresecence microscopy at 24 h following combined treatment with radiation and rucaparib in PC3 and LNCaP cells.

30589644 27515310 23565244
In vivo Rucaparib is not toxic but significantly enhances temozolomide-induced TGD in the DNA repair protein-competent D384Med xenografts. Pharmacokinetics studies also show that Rucaparib is detected in the brain tissue, which indicates that Rucaparib has potential in intra-cranial malignancy therapy. [4] Rucaparib significantly potentiates the cytotoxicity of topotecan and temozolomide in NB-1691, SH-SY-5Y, and SKNBE (2c) cells. Rucaparib enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts. [5]

Protocol

Kinase Assay:[1]
- Collapse

Ki Determination:

Inhibition of human full-length recombinant PARP-1 by [32P]NAD+ incorporation is measured. The [32P]ADP-ribose incorporated into acid insoluble material is quantified using a PhosphorImager. Ki is calculated by nonlinear regression analysis.
Cell Research:[4]
- Collapse
  • Cell lines: D425Med, D283Med and D384Med cells
  • Concentrations: 0.4 μM
  • Incubation Time: 3 or 5 days
  • Method: Medulloblastoma cell lines are seeded in 96-well plates at a density of 1 × 103, 3 × 103 and 3 × 103, respectively. At 24 hours (D384Med) or 48 hours (D283Med and D425Med) after seeding, the cells are exposed to various concentrations of temozolomide in the presence or absence of 0.4 μM Rucaparib. After 3 days (D425Med and D384Med) or 5 days (D283Med) of culture, cell viability is evaluated by a XTT cell proliferation kit assay. Cell growth is expressed as a percentage in relation to DMSO or 0.4 μM Rucaparib-alone controls. The concentration of temozolomide, alone or in combination with Rucaparib that inhibited growth by 50% (GI50) is calculated. The potentiation factor 50 (PF50) is defined as the ratio of the GI50 of temozolomide in the presence of Rucaparib to the GI50 of temozolomide alone.
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: CD-1 nude mice bearing established D283Med xenografts
  • Formulation: Normal saline
  • Dosages: 1 mg/kg
  • Administration: One or four daily by i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.35 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing. 		10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.36
Formula

C19H18FN3O.H3PO4
CAS No. 459868-92-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03954366 Recruiting Drug: Rucaparib|Drug: Rosuvastatin|Drug: Oral Contraceptives Neoplasms Clovis Oncology Inc. May 8 2019 Phase 1
NCT03824704 Recruiting Drug: Rucaparib|Drug: Nivolumab Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|High Grade Serous Carcinoma|Endometrioid Adenocarcinoma Clovis Oncology Inc.|Bristol-Myers Squibb|Foundation Medicine May 15 2019 Phase 2
NCT03413995 Recruiting Drug: Rucaparib Prostate Cancer Metastatic Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Clovis Oncology Inc. September 10 2018 Phase 2
NCT03572478 Recruiting Drug: Rucaparib|Drug: Nivolumab Prostate Cancer|Endometrial Cancer University of Chicago|Bristol-Myers Squibb|Clovis Oncology Inc. August 14 2018 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

  • Selective PARP Inhibitors

    AG-14361 : PARP1-selective, Ki<5 nM.

  • Selective PARP Inhibitors

    UPF 1069 : PARP2-selective, IC50=0.3 μM.

  • Most Potent PARP Inhibitor

    MK-4827 (Niraparib) : PARP1, IC50=3.8 nM; PARP2, IC50=2.1 nM.

  • PARP Inhibitor in Clinical Trial

    Iniparib (BSI-201) : Phase III for solid tumors.

  • Newest PARP Inhibitor

    PJ34 HCl New : PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.

Related PARP Products

  • G007-LK New

    G007-LK is a potent and selective tankyrase inhibitor with IC50 of 46 nM and 25 nM for TNKS1/2, respectively.

  • NU1025 New

    NU1025 is a potent PARP inhibitor with IC50 of 400 nM.

  • SCR7 New

    SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.

  • Olaparib (AZD2281, Ku-0059436)

    Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

    Features:A potent PARP inhibitor (currently in late stage clinical trials).

  • Veliparib (ABT-888)

    Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.

    Features:Increases the efficacy of common cancer therapies such as radiation and alkylating agents.

  • Talazoparib (BMN 673)

    Talazoparib (BMN 673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.

    Features:Most potent and selective PARPi reported thus far.

  • Iniparib (BSI-201)

    Iniparib (BSI-201) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC). Phase 3.

  • PJ34 HCl

    PJ34 HCl is the hydrochloride salt of PJ34, which is a PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.

    Features:Water-soluble PARP1/2 inhibitor with >10,000-fold potentcy vs. 3-aminobenzamide (prototypical PARP inhibitor). Potential uses in cardiovascular diseases (stroke, cerebral ischemia, & myocardial ischemia).

  • AG-14361

    AG14361 is a potent inhibitor of PARP1 with Ki of <5 nM in a cell-free assay. It is at least 1000-fold more potent than the benzamides.

    Features:The 1st high-potency PARP-1 inhibitor with the specificity & in vivo activity to enhance chemotherapy and radiation therapy of human cancers.

  • A-966492

    A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with Ki of 1 nM and 1.5 nM, respectively.

    Features:A promising, structurally diverse benzimidazole analogue that is being further characterized preclinically.

Tags: buy Rucaparib (AG-014699,PF-01367338) phosphate | Rucaparib (AG-014699,PF-01367338) phosphate supplier | purchase Rucaparib (AG-014699,PF-01367338) phosphate | Rucaparib (AG-014699,PF-01367338) phosphate cost | Rucaparib (AG-014699,PF-01367338) phosphate manufacturer | order Rucaparib (AG-014699,PF-01367338) phosphate | Rucaparib (AG-014699,PF-01367338) phosphate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID